TY - JOUR AU - Nagar, Lalit AU - Lamo, Ringzin AU - K, Mishra J AU - N, Dwivedi K PY - 2020/03/24 Y2 - 2024/03/28 TI - Evaluation of Rasayaṇa activity of Rudanti (Capparis moonii Wight.) in the Management of Rajayakshma (Pulmonary tuberculosis) JF - International Journal of Ayurvedic Medicine JA - IJAM VL - 11 IS - 1 SE - Research Articles DO - 10.47552/ijam.v11i1.1361 UR - https://ijam.co.in/index.php/ijam/article/view/1361 SP - 55-60 AB - <p>It is estimated that about 1/3rd world’s population is infected by Mycobacterium tuberculosis. It kills more adults in India than any other infectious diseases. In 2018, India was able to achieve a Total Notification of 21.5 Lakh TB cases of which 25 % was from the private sector. Majority of the TB burden is among the working age group. The 89% of TB cases come from the age group of 15-69 years. About 2/3 of the TB cases are Males. Uttar Pradesh, with 17% of population of the country, is the largest contributor to the TB cases in with 20% of the total notifications, accounting to about 4.2 Lakh cases (187 cases/ lakh population). Aim and objective: This study was intended to evaluate the <em>rasayaṇa</em> effect of <em>Rudanti</em> (<em>Capparis moonii</em> wight.) as an adjunct to anti-tubercular drugs in the management of <em>Rajayakshma</em> (PTB). Methodology: This is a single blind therapeutic control randomized clinical trial consisting of 100 patients divided in to two groups. Group A patients were treated with DOTS and group B were treated with DOTS along with <em>Rudanti</em> powder 5 gm BD for 6 months. Conclusion: This study shows that by incorporating an herbal rejuvenative in the management of PTB, a chronic debilitating disorder, had an additive effect. <em>Rudanti</em> powder can be easily administered as an adjunct to DOTS. <em>Rudanti</em> has hepatoprotective properties, which remunerate the hepatotoxicity known to cause by DOTS drugs. Improved weight gain in TG patients in comparison to CG indicates the accessory effect of <em>Rudanti</em>.</p> ER -